News
PVLA
157.77
+1.83%
2.84
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)
TipRanks · 2d ago
Palvella Therapeutics price target lowered to $207 from $210 at Truist
TipRanks · 2d ago
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
TipRanks · 2d ago
Palvella Therapeutics CEO joins Canaccord Genuity Growth Conference fireside chat
PUBT · 2d ago
Palvella Therapeutics price target raised to $232 from $227 at Canaccord
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), OrthoPediatrics (KIDS) and Palvella Therapeutics (PVLA)
TipRanks · 2d ago
Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating
TipRanks · 2d ago
High-Risk Warning for Investors in Palvella Therapeutics Securities
TipRanks · 2d ago
Palvella Therapeutics Charts Clear Path From Data To Launch
TipRanks · 2d ago
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Reuters · 2d ago
Tyra Biosciences Q2 net loss widens on higher R&D expenses
Reuters · 3d ago
Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026
Reuters · 3d ago
Niagen Bioscience Q2 net sales fall, missing estimates
Reuters · 3d ago
Dianthus Therapeutics Q2 net loss widens as R&D costs rise
Reuters · 3d ago
Lipocine Q2 net loss widens as revenue declines
Reuters · 3d ago
Palvella Therapeutics Q2 net loss widens on higher expenses
Reuters · 3d ago
Palvella details QTORIN progress and Nasdaq uplisting milestones
TipRanks · 3d ago
Palvella Therapeutics GAAP EPS of -$1.52 misses by $0.34
Seeking Alpha · 3d ago
Palvella net loss widens 130.88% to $21.87 million in Q2 FY26; R&D expenses more than doubled to $12.47 million
PUBT · 3d ago
Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate
Benzinga · 3d ago
More
Webull provides a variety of real-time PVLA stock news. You can receive the latest news about Palvella Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.